TOURMALINE-MM2 study on NINLARO fails to deliver desired results

This article was originally published here

The late-stage TOURMALINE-MM2 trial featured 705 adult patients who are newly diagnosed with multiple myeloma and are not candidates for transplant. NINLARO is an oral proteasome inhibitor, which

The post TOURMALINE-MM2 study on NINLARO fails to deliver desired results appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply